Integrase Inhibitor Prescribing Disparities in the DC and Johns Hopkins HIV Cohorts.
Open Forum Infect Dis 2021;
8:ofab338. [PMID:
34631925 PMCID:
PMC8496514 DOI:
10.1093/ofid/ofab338]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2021] [Accepted: 06/29/2021] [Indexed: 11/20/2022] Open
Abstract
Integrase inhibitors (INSTIs) are recommended by expert panels as initial therapy
for people with HIV. Because there can be disparities in prescribing and uptake
of novel and/or recommended therapies, this analysis assessed potential INSTI
prescribing disparities using a combined data set from the Johns Hopkins HIV
Clinical Cohort and the DC Cohort. We performed multivariable logistic
regression to identify factors associated with ever being prescribed an INSTI.
Disparities were noted, including clinic location, age, and being transgender.
Identifying disparities may allow clinicians to focus their attention on these
individuals and ensure that therapy decisions are grounded in valid clinical
reasons.
Collapse